American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias, This official statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was approved by the ATS board of directors, June 2013 and by the ERS Steering Committee, March 2013, in Am Respir Crit Care Med, vol. 188, n. 6, 2013, pp. 733-748, PMID24032382.
Hyldgaard C, Hilberg O, Muller A, Bendstrup E, A cohort study of interstitial lung diseases in central Denmark, in Respir Med, vol. 108, n. 5, 2014, pp. 793–799, PMID24636811.
García-Sancho C, Buendía-Roldán I, Fernández-Plata MR, Navarro C, Pérez-Padilla R, Vargas MH, Loyd JE, Selman M. Buendía-Roldán I, Fernández-Plata MR, et al., Familial pulmonary fibrosis is the strongest risk factor for idiopathic pulmonary fibrosis, in Respir Med., vol. 105, n. 12, 2011, pp. 1902–1990, PMID21917441.
Selman M, King TE, Pardo A, Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy, in Ann Intern Med., vol. 134, n. 2, 2001, pp. 136–151, PMID11177318.
Mathai S, et al., Genetic susceptibility and pulmonary fibrosis, in Curr Opin Pulm Med, vol. 20, n. 5, 2014, pp. 429–435, PMID25022318.
Kropski JA, Mitchell DB, Markin C, et al., A novel dyskerin (DKC1) mutation is associated with familial interstitial pneumonia, in Chest, 2014, PMID24504062.
Flaherty KR, Mumford JA, Murray S, Kazerooni EA, Gross BH, Colby TV, Travis WD, Flint A, et al., Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia, in Am J Respir Crit Care Med., vol. 168, n. 5, 2007, pp. 543-548, PMID12773329.
King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, for the ASCEND Study Group., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis, in N Engl J Med, vol. 370, n. 22, 2014, pp. 2083–2092, PMID24836312.
Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, M Costabel U, Cottin V, Flaherty KR, for the INPULSIS Trial Investigators., Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis, in N Engl J Med, vol. 370, n. 22, 2014, pp. 2071–2082, PMID24836310.
Bjoraker JA, Ryu JH, Edwin MK, Myers JL, Tazelaar HD, Schroeder DR, Offord KP, Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis, in Am J Respir Crit Care Med., vol. 157, n. 1, 1998, pp. 199-203, PMID9445300.
Peljto AL, Zhang Y, Fingerlin TE, Ma SF, Garcia JG, Richards TJ, Silveira LJ, Lindell KO, et al., Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis, in JAMA, vol. 309, n. 21, 2013, pp. 2232–2239, PMID23695349.
Stock CJ, Sato H, Fonseca C, Banya WA, Molyneaux PL, Adamali H, Russell AM, Denton CP, et al., Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis, in Thorax, vol. 68, n. 5, 2013, pp. 436–441, PMID23321605.
The Idiopathic Pulmonary Fibrosis Clinical Research Network, Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis, in N Engl J Med., vol. 370, n. 22, 2014, pp. 2093–2102, PMID24836309.